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Abstract
Background: The health-related quality of life (HRQL) of people living with HIV infection is an important
consideration in HIV management. The PROQOL-HIV psychometric instrument was recently developed
internationally as a contemporary, discriminating HIV-HRQL measure incorporating influential emotional dimensions
such as stigma. Here we present the first within-country results of PROQOL-HIV using qualitative and quantitative
data collected from a West Australian cohort who participated in the development and validation of PROQOL-HIV,
and provide a comprehensive picture of HRQL in our setting.
Methods: We carried out a secondary analysis of data from Australian patients who participated in the international
study: 15 in-depth interviews were conducted and 102 HRQL surveys using the PROQOL-HIV instrument and a
symptom questionnaire were administered. We employed qualitative methods to extract description from the
interview data and linear regression for exploration of the composite and sub-scale scores derived from the survey.
Results: Interviews revealed the long-standing difficulties of living with HIV, particularly in the domains of intimate
relationships, perceived stigma, and chronic ill health. The novel PROQOL-HIV instrument discriminated impact of
treatment via symptomatology, pill burden and treatment duration. Patients demonstrated lower HRQL if they
were: newly diagnosed (p=0.001); naive to anti-retroviral treatment (p=0.009); reporting depression, unemployment
or a high frequency of adverse symptoms, (all p<0.001). Total HRQL was notably reduced by perceived stigma with
a third of surveyed patients reporting persistent fears of both disclosing their HIV status and infecting others.
Conclusions: The analysis showed that psychological distress was a major influence on HRQL in our cohort. This
was compounded in people with poor physical health which in turn was associated with unemployment and
depression. People with HIV infection are living longer and residual side effects of the earlier regimens complicate
current clinical management and affect their quality of life. However, even for the newly diagnosed exposed to less
toxic regimens, HIV-related stigma exerts negative social and psychological effects. It is evident that context-specific
interventions are required to address persistent distress related to stigma, reframe personal and public perceptions
of HIV infection and ameliorate its disabling social and psychological effects.
Keywords: HIV/AIDS, Health related quality of life, Health status indicators, Stigma, Symptoms, PROQOL-HIV
* Correspondence: s.herrmann@murdoch.edu.au
1Institute for Immunology & Infectious Diseases, Royal Perth Hospital &
Murdoch University, Murdoch, Perth, Australia
Full list of author information is available at the end of the article
© 2013 Herrmann et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Herrmann et al. Health and Quality of Life Outcomes 2013, 11:56
http://www.hqlo.com/content/11/1/56
Background
Antiretroviral therapy (ART) has slowed progression of
HIV infection to AIDS, and significantly reduced mor-
bidity and mortality in people living with HIV (PLWH)
who have access to treatment [1]. In addition, increased
tolerability of ART [2], reduced pill burden and dosing
frequency have been positive influences on health-
related quality of life (HRQL) facilitated by medication
adherence [3]. However, many PLWH who survived the
early era of combination therapy experience residual
disabling effects of the drugs such as: lipodystrophy [4],
neuropathy [5], and persistent immunosuppression [6],
which can impair quality of life. Comorbidities such as
hepatitis C may add an additional physical and psycho-
logical burden [7-9]. Social circumstances such as
unemployment and inadequate housing [10], and emo-
tional stressors—often related to HIV-related stigma [11]
—can also diminish HRQL [12]. A marked feature of
HIV-related stigma is that PLWH are often attributed as
agents responsible for the potentially contagious and
fatal infection, and associated with practices marked as
deviant by many societies [13]. Significantly, stigma can
have an intrapersonal dimension when acceptance of
society’s views leads to a form of self discrimination
where one feels deserving of society’s disapprobation
[13,14] and this internalised stigma appears predictive of
significant outcomes for PLWH [15,16]. Notably, stigma
is a complex social construct and it is likely to impact
differentially according to an individual’s social context
[17-19]. Evidently, these stressors continue to exert an
influence on health-related quality of life (HRQL) [20]
despite advances in clinical care.
Measures to assess the effect of drugs for the treat-
ment of HIV on health status and wellbeing were intro-
duced in 1991 [21] and while HRQL matters irrespective
of treatment status—since the purpose of ART is to sup-
press the virus—it is necessary to ensure that HRQL is
not compromised during this process. Accordingly, mea-
sures are commonly used to either detect changes in
HRQL that may make drug or other new interventions
more or less acceptable to patients and prescribers, or to
indicate what other pressures, independent of treatment,
may affect people living with HIV. A new Patient-
Reported Outcomes (PRO) questionnaire to measure the
HRQL in people living with HIV was recently developed
and validated internationally with the participation of
our centre [22,23]. In this paper, we juxtapose the hith-
erto unreported qualitative data and the discrete quanti-
tative data obtained from the Australian participants.
The aim of this study was to enhance understanding of
the major factors impacting health-related quality of life
in our cohort. By focusing on this local perspective, the
work provides an explanatory rather than predictive ap-
proach to understanding the relationship between HRQL
and physical, social and psychological distress, including
HIV-related stigma, on a specific sample in a particular
context.
Methods
Study design and setting
Semi-structured interviews with fifteen patients and sur-
vey data from 102 (out of 106 administered) respondents
were analysed. It had been determined that fifteen inter-
views were sufficient for a within-country analysis based
on the research of others into qualitative data saturation
[24], and the sample size for a within-country analysis of
the PROQOL-HIV questionnaire had been powered for
100 patients. This figure considered the number of con-
ceptual dimensions needed to ensure a final factor
model with reliable factor loadings in exploratory factor
analysis [23,25]. Patients with HIV infection, over the
age of 18 years and able to give informed consent, were
eligible for inclusion in the study. Patients were recruited
during scheduled clinic visits to the Immunology Clinic at
Royal Perth Hospital, a tertiary ambulatory facility. The fif-
teen interviewees were informed about the study by the
unit social worker, and patients subsequently contacted
the researcher to arrange an appointment at an agreed
venue. These participants were chosen to reflect a mix of
age, gender and mode of HIV transmission. Recruitment
for the survey phase was conducted at consecutive clinics
from June to October 2008. Patients with sufficient time
before their appointment with the physician were invited
to complete the survey. Of 109 patients approached, two
patients declined to participate and data from five surveys
were not included in the final analysis because they were
incomplete. The study was approved by the Royal Perth
Hospital Ethics Committee (2007/115).
Interview methods
Two trained interviewers conducted semi-directed inter-
views of 60 to 120 minutes duration which were recorded
and transcribed verbatim. The interview guide comprised
107 questions of which the first five were open-ended seek-
ing participants’ experiences of the impact of HIV on their
daily lives and their quality of life in general. The latter 102
questions were categorised into topics of self and body
care, daily activities, physical activities, health perception,
energy/fatigue, cognitive functioning, social relationships,
emotions and treatment. Participants were invited to qual-
ify their responses. Hard copies of the transcripts were
printed and patient interview data were examined by the
two interviewers, independently, and several themes were
identified and discussed. The transcripts were subsequently
imported into the NVivo 8 qualitative software programme
(QSR International Pty Ltd) where the verbatim was
catalogued under theme headings called nodes. Analysis in
NVivo facilitated the exploration of recurring themes and
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concepts, and drew attention to commonalities and vari-
ation between the verbatim of the interviewees.
Questionnaires
The PROQOL-HIV questionnaire and a 31-item HIV
symptom index [26] modified to include self-reported
signs of fat redistribution and symptoms not found in
the list, were administered concurrently. The question-
naires were completed in face-to-face communications
to allow the participants the opportunity to ask ques-
tions and make comments during their completion.
The global PROQOL-HIV score, as used in analyses, is
a composite measure based on 38-items, comprising
eight sub-scales (factors) that encompass the following
domains: Physical health and symptoms (PHS), emo-
tional distress (ED), health concerns (HC), body change
(BC), intimate relationships (IR), social relationships
(SR), stigma (ST). The last sub-scale, treatment impact
(TI) is omitted in a seven-factor score so that the ques-
tionnaire is equally applicable to patients irrespective of
treatment status. The sub-scales were derived from
summed Likert item values (range 0–4 points) expressed
as a final score on a 0–100 scale with higher values indi-
cating better HRQL; these were then averaged to arrive
at the composite global score. The main properties, in-
cluding the validity and reliability of the questionnaire
and comparisons with other commonly used HRQL in-
struments, are described elsewhere [23], but briefly, the
score’s reliability using Cronbach’s alpha was 0.936 (95%
CI = 0.929-0.943); and the intra-class correlation coeffi-
cient (ICC) was based on an assessment of 34 patients
for temporal stability and resulted in a score of 0.86
(95%, CI=0.701-0.959).
Clinical characteristics
Plasma HIV RNA levels were determined using a
polymerase chain reaction assay with a lower limit of
detection of 40 copies/ml (Roche). The CD4+T cell
lymphocyte count (mm3) was measured using the
current standard flow cytometry assay (FACScanto™
flow cytometer, Becton Dickinson). Histories of HIV/
AIDS diagnosis, co-morbidities and treatments were
collected from the patients and verified using their med-
ical records. Adherence to ART was measured as the
number of self-reported missed doses in the two weeks
preceding the study visit and was concordant with the
standard clinic practice of recording level of adherence,
longitudinally, for all PLWH attending the clinic [27].
Analysis
Sociodemographic, biomedical and psychometric data
obtained from the PROQOL participants were compared
across treatment groups (no HIV therapy, or treatment
based on a protease-inhibitor or a non-nucleoside reverse
transcriptase inhibitor) using Fisher or Kruskal-Wallis tests
as appropriate. Quantitative analysis of the PROQOL scores
was exploratory, with an aim to identify correlates of HRQL
and assess their relative association across contributing
sub-scales. To this end, both the composite and sub-scale
scores were analysed as dependent variables in a series of
linear regression models which considered a suite of poten-
tial correlates as independent variables both univariately
and in blocks according to type: sociodemographic,
treatment-related, biological or clinical. Results of the initial
univariate analyses are reported as mean (SE) changes in
scores, and the block multivariate analyses as model R2
values which measure the proportion of the variation in
scores explained by the variable sets considered as a whole.
This approach was chosen to focus on relative impact
according to correlate type, thereby lending itself to more
meaningful interpretation in our context. Secondary multi-
variate analyses were then undertaken to further explore
several effects highlighted in the univariate analyses, in par-
ticular to assess independence of specific noteworthy fac-
tors having a univariate p < 0.05. Analyses were undertaken
using TIBCO Spotfire S+ 8.2 for Windows (TIBCO Soft-
ware Inc., Palo Alto, CA).
Results of interviews
Clinical and sociodemographic data
Most of the 15 interviewees were Caucasian men, three
were SE Asian and two identified as being of Aboriginal
ancestry. The median year of HIV diagnosis was 2001,
and the mean (± SD) age was 41 yrs (±10.5), CD4 T-cell
count 542 copies/ml (±332.2), and percent of lympho-
cyte count 25.5% (±9.7) (Table 1). Of the 3/15 patients
who had a detectable viral load, two were not on current
ART and one had a history of poor adherence. Symp-
toms were frequently reported (1–20 symptoms/31) at
an average of eight symptoms per person. The most
common were gastrointestinal (11 patients) followed by
sleep difficulties (10), fatigue (10), and skin dry/itching
(9). Eight patients smoked and eleven reported current
use of alcohol. Seven lived alone, five in a couple, two
with family members and two with children. Six patients
were in paid employment and two were students. All
completed school to at least age 15 and six were tertiary
educated. Co-morbidities were described by 4/15 (26%):
hepatitis C (HCV) (2 patients), pulmonary hypertension
(1), Type 2 diabetes (1), and chronic back pain (1) and
four (26%) reported current depression, two were treated.
Three patients had lipodystrophy attributed to previous
treatment with thymidine analogue nucleoside reverse
transcriptase inhibitors.
Interview verbatim: aspects of living with HIV
Quotes illustrating four dimensions of living with HIV
(Table 2) are presented: (1) emotional/social, (2) physical,
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(3) impact of treatment and (4) understanding of quality
of life. Most patients perceived HRQL as having HIV or
non-HIV influences. For some it involved feeling happy,
and having supportive networks of family and/or friends,
a satisfactory income and access to potent and effective
treatments. The patients who experienced lower HRQL
described co-morbidities, a higher frequency of stigma
fears, self-reported adverse symptoms and were more
likely to be on disability pensions.
Emotional and social impact
Feelings of social stigma triggered by HIV were associ-
ated with fear and anxiety in 11 out of the 15 inter-
viewees despite a degree of self-reported adjustment to
living with HIV. A fear of transmitting HIV inadvertently
or in a situation where one was powerless to protect
others, for example, during a car accident, was intense for
some individuals. A minor cut while preparing food
resulted in interviewees starting the process again. One
participant abandoned a profession in catering because of
this concern. There was an aversion to disclosing HIV
sero-status in any circumstance and a fear of being ‘outed’
by the appearance of ill health or being seen attending the
hospital clinic. Anxiety about disclosure to employers, sex-
ual partners and parents and, for two of the women, their
children, was considered most stressful. Some perceived
career options to be limited. Attitudes of others featured
strongly; stigma related to disease but also sexual identity,
for example a heterosexual man feared homophobia. HIV
impacted on work opportunities for those with ill health
and choice of work generally. Feelings of sadness, shame
and inferiority were common. The greatest restrictions for
over half of participants were around sexuality: reduced
spontaneity and avoidance of sexual intercourse. The legal
and moral requirement to disclose to prospective partners
and, potentially, employers weighed heavily. Restrictions
to travel opportunities were perceived, compounded by
concerns over travelling with medication, disclosing HIV
status on entry to some countries, and fear of becoming ill
while holidaying. Some withdrew by degrees from social
activities. The loneliness of chronic illness was described
by one participant who perceived that friendships had
fallen away since illness has altered his appearance and re-
lationships with health care providers are tense because of
his inability to ‘get well’ despite their ‘efforts’. However,
approximately half of the sample expressed either accept-
ance or adjustment of their HIV serostatus and two
reported receiving support following disclosure.
Physical impact
With regard to physical activity, some patients were lim-
ited by disability related to co-morbidity, whilst in others
symptoms of pain and/or fatigue limited activity and af-
fected motivation resulting in feelings of social isolation.
Activity that might result in transmission of HIV was
avoided by interviewees and some had given up pleasur-
able body contact sports and professions which they per-
ceived might lead them to spill blood.
Table 1 Characteristics of the 15 interviewees
Patient Age (yrs) Gender m/f/o Transmission mode Year CDC CD4 (%) Viral Load (log) HAART* Duration (mths)
1 48 m msm 1985 C 35 <40 3TC/AZT/ABC 109
2 31 m msm 2004 A 30 <40 3TC/AZT/EFV 42
3 41 f unknown 1987 B 22 <40 FTC/TDF/LPV/RTV 180
4 66 m hetero 1997 C 20 <40 3TC/DDI/RTV/ATV 114
5 28 f hetero 1994 C <6% 4.8 no current HAART 156
6 36 m msm 2003 A 28 1.84 3TC/AZT/NVP 33
7 55 m msm 1988 A 34 <40 3TC/ ABC/ LPV/RTV 78
8 47 m msm 2002 A 26 <40 3TC/ ABC/ LPV/RTV 36
9 45 m msm 2001 C 28 <40 3TC/TDF/NVP 72
10 38 m msm 2006 A 17 <40 3TC/AZT/EFV 9
11 26 f hetero 1998 A 49 <40 3TC/AZT/EFV 72
12 32 f IDU 2001 A 32 3.92 no current HAART 72
13 44 m msm 1986 C 21 2.16 3TC/AZT/ABC 156
14 37 m msm 2005 A 30 <40 3TC/ABC/RTV/ATV 26
15 42 m msm 2002 C 20 <40 3TC/AZT/EFV 63
Abbreviations: msm = men who have sex with men, hetero= heterosexual, IDU = injecting drug use. HAART= highly active antiretroviral therapy; 3TC=
lamivudine, FTC= emtricitabine, AZT= zidovudine, ABC = abacavir, TDF = tenofovir, DDI= didanosine, NVP= nevirapine, EFV= efavirenz, LPV=lopinavir, RTV=
ritonavir, ATV= atazanavir; 8/13 patients on a BD regimen, mean number of pills = 3.4, median=3.
CDC = stage at first presentation.
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Table 2 Interviews: Themes emerging from narratives (N=15)
Emotional and social impact The fact that (it’s, a) it’s a scary thing for people that don’t have it and a scary thing for people that do have it, it’s
just a terrifying thing. . . (woman, 28 yrs).
What disturbs me most about HIV is even though there is a lot of information out there, there are a lot of people
that still are quite ignorant and they’re still quite fearful of HIV (man, 31 yrs).
That my mother will find out. . .(man, 42 yrs).
I am scared that I tell them and then it will be different. They would treat me differently (woman, 28 yrs).
I’m afraid of dying. . .getting sick and not being able to take care of my children. I’m afraid of my children finding
out like that’s probably my biggest fear in this world is when my children find out (woman, 32 yrs).
Oh massively restricted in the sexual sense (woman, 26 yrs).
The fear that something may happen to me and I’m in a car accident....and someone tries to help me and I’m
bleeding profusely and I pass it on to them (woman, 32 yrs).
Sometimes if I’m cooking. . . silly thoughts of cutting myself (man, 37 yrs).
When they talk about people there is a disgust in the way they talk there’s disgust and it really deeply hurts because
I have HIV and I don’t think that I’m disgusting (woman, 28 yrs).
Sometimes it’s really difficult. . . like can be very isolating. Sometimes I feel like no one really understands and it’s
very secretive as well like no one really knows, I don’t want people knowing (woman 32 yrs).
. . .the friends that I did have put distance between us. . .. Separated themselves from me because it’s all got a bit
hard or whatever (man, 47 yrs).
That fear of possibly infecting him. I think the guilt eventually killed it (man, 42 yrs).
Physical impact I went straight back to work as soon as I could- (work) was just a very lucky distraction to have (man, 38 yrs).
I get tired very quick but don’t generally stop me doing anything I want to do. . .my problem is not wanting to do
anything. . .it’s the motivation I don’t have (woman, 41 yrs).
Tired and exhausted both (man, 66 yrs).
I might have three or four bad days in a row and I have to ring up and take it off work and there’s no employer. . .
they can’t put up with that for too long (man, 47 yrs).
. . .any sort of activity that involves danger, all the risk of you know getting cut or something like that I just don’t do
(woman, 32 yrs).
Treatment impact I look at them making me sick, making me vomit like just want to vomit already just looking at them (woman, 28
yrs).
The drugs, the drugs are great. I can’t complain I haven’t had any side effects (man, 55 yrs).
None. . . problem is just taking them in front of people (man, 37 yrs).
I never had a eight hour sleep. . . there was not such a thing as an eight hour sleep (man, 44 yrs).
Perceptions of quality of life The way you do to get to do the things you like to do, like what kind of barriers do you face like - do you have the
support networks and all that sort of stuff (man, 66 yrs).
. . . means enjoying yourself, being happy. . . feeling good within yourself and about the people around you. I don’t
have that any more (man, 47 yrs).
I think within the realms of HIV itself, I would think that my health is good. . . um. . . but within the realm of the
general population, I would say that my health is quite bad. . . (man, 42 yrs).
Since my medication my life’s actually been enhanced (man 37 yrs).
I’ve got the best drugs, good treatment at the hospital - I can still work (man, 38 yrs).
It’s been up and down but it’s now it’s pretty good according to all the numbers and results and things, I’m pretty
well normal. . . (woman, 41 yrs).
I realised it’s all psychological really (woman, 32 yrs).
I suppose for two thirds of my life, because . . . I have been living with HIV for a third of my life, I lived a quality of
life where I didn’t have to think about everything I just did what I wanted to do basically within ones responsibilities
and obligations. Now through HIV my quality of life has changed in that now everything I do has to be considered
(man, 45 yrs).
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Impact of treatment
The interviewees who started ART pre-2000 described
effects of pill burden, frequent dosing intervals and re-
sidual side effects. One developed immune restoration
syndrome and a disfiguring skin condition. His experi-
ence of high-dose steroids and frequent changes of ART
were debilitating and he felt unable to work or maintain
an intimate relationship. Another interviewee had a
long-standing history of non-adherence to ART and was
hospitalised with severe immunodeficiency. This re-
spondent took medication secretly, as did others. How-
ever, the majority viewed ART positively, as improving
their health despite the effects of long-term toxicities.
Results of the PROQOL-HIV survey questionnaire
Clinical and sociodemographic data
The data were collected from 102 patients (15% female)
aged between 24 and 71 years. Socio-demographic
characteristics can be found in Table 3. Transmission
was mainly through sexual contact (94%) and nearly
40% of participants lived alone. All but two patients
reached at least secondary school level, and 80% were
employed. The most common co-morbidity was depres-
sion (24%) followed by HCV (17%), psychiatric disorder
(5%), cardiovascular disease (3%) and hepatitis B (2%).
Of the patients with depression, 77% were treated with
antidepressants and 30% had hepatitis C. Most patients
were treated with ART (87/102), two patients had
stopped treatment, and 13 were ART naive. Amongst
treated patients, 76% reported 100% adherence over the
last two weeks, and of the 47% on a protease inhibitor
(PI) based regimen 56% were taking ART once daily
compared with 83% of those on a non-nucleoside
reverse-transcriptase inhibitor (NNRTI) regimen. An
undetectable viral load was recorded in 85% of patients
and the average CD4 T-cell percentage was 26%.
Table 3 Characteristics of PROQOL participants
Variables ALL Not on Rx NNRTI PI p-value
N = 102 N = 15 N = 46 N = 41
Female 15 (14.7%) 4 (26.7%) 7 (15.2%) 4 (9.8%) p=0.3
Age 46 (37–53.8) 41 (32.5-49.5) 48 (37–56.5) 45 (40–53) p=0.4
Transmission p=0.08
Heterosexual/other 42 (41.2%) 10 (66.7%) 21 (45.7%) 11 (26.8%)
IDU 6 (5.9%) 0 (0%) 3 (6.5%) 3 (7.3%)
MSM 54 (52.9%) 5 (33.3%) 22 (47.8%) 27 (65.9%)
Married 34 (33.3%) 5 (33.3%) 17 (37%) 12 (29.3%) p=0.7
Caucasian 80 (78.4%) 9 (60%) 37 (80.4%) 34 (82.9%) p=0.2
Living alone 40 (39.2%) 8 (53.3%) 16 (34.8%) 16 (39%) p=0.5
Post-secondary 37 (36.3%) 6 (40%) 17 (37%) 14 (34.1%) p=0.9
Unemployed/sickness benefits 18 (17.6%) 2 (13.3%) 3 (6.5%) 13 (31.7%) p=0.007
Smoker ≥ 2 cigarettes/day 41 (40.2%) 4 (26.7%) 19 (41.3%) 18 (43.9%) p=0.0002
Alcohol ≥ 2 glasses/day 15 (14.7%) 1 (6.7%) 7 (15.2%) 7 (17.1%) p=0.5
Diagnosed < 2 years 16 (15.7%) 8 (53.3%) 6 (13%) 2 (4.9%) p=0.7
Time since diagnosis (years) 7.3 (2.9-15.6) 1.5 (0.8-3.8) 6.8 (3.2-11.9) 13.2 (6.2-18.9) p<0.0001
Body mass index 24.3 (22–28) 23.6 (22–28) 25.4 (23–28) 23.9 (22–27) p=0.5
CD4 T cells 530 (376–733) 546 (512–695) 591 (386–853) 455 (323–638) p=0.1
Undetectable VL 77 (75.5%) 2 (13.3%) 43 (93.5%) 32 (78%) p<0.0001
Time on ART (years) 4.2 (0.8-11.8) - 4.4 (2.1-9.9) 10.7 (3.2-13.6) p<0.0001
On non-ART medication 38 (37.3%) 3 (20%) 15 (32.6%) 20 (48.8%) p=0.1
ART pill burden (tablets/day) 3 (2–5) - 2.5 (2–3) 4 (3–5) p<0.0001
Non-adherent to ART 18 (17.6%) - 7 (15.2%) 11 (26.8%) p=0.2
Depressive 26 (25.5%) 3 (20%) 8 (17.4%) 15 (36.6%) p=0.1
Other comorbidity 56 (54.9%) 8 (53.3%) 20 (43.5%) 28 (68.3%) p=0.07
Sexual dysfunction 25 (24.5%) 4 (26.7%) 9 (19.6%) 12 (29.3%) p=0.5
Number symptoms (total) 5 (2–10) 4 (1–10.5) 5 (1–8) 8 (5–12) p=0.01
For categorical variables, values are N(%) and the p-value corresponds to a Fisher exact test of equal proportions across treatment groups; for continuous
variables, values are median (interquartile range) with the p-values reflecting differences across the treatment groups as assessed by a Kruskal-Wallis test.
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Table 4 Linear regression estimates of univariate predictors of mean (SE) increase/reduction (+/−) in PROQOL subscale and global scores (body of table),
together with the percent of the score variances explained by fitting joint models of covariate blocks as grouped according to indication of
sociodemographic, treatment, biomedical or clinical factors (R2×100)
Emotional Health Social Intimate Stigma Body Phys. Health
& Symptoms
Treatment
Impact^
Global
Distress Concerns Relationships Relationships Changes
7-factor^ 8-factor
All patients
Mean (SE) 64.89 (2.63) 54.90 (2.64) 72.55 (2.58) 51.63 (2.98) 43.32 (3.10) 66.48 (2.58) 71.36 (2.14) - 60.62 (2.01) -
Treated patients
Mean (SE) 65.16 (2.88) 57.69 (2.80) 73.41 (2.79) 52.01 (3.17) 46.66 (3.40) 66.52 (2.73) 71.05 (2.27) 81.08 (1.63) 61.66 (2.21) 64.07 (2.06)
Sociodemographic factors
Male gender +8.18 (7.43) +13.56 (7.36) +2.01 (7.33) −9.81 (8.41) +9.77 (8.71) +4.18 (7.32) +3.09 (6.05) +7.36 (4.86) +4.29 (5.67) +4.50 (6.18)
Transmission (ref: heterosexual/unknown)
IDU +11.61 (11.65) +14.29 (11.65) −0.89 (11.49) +2.28 (13.14) +27.39 (13.43)* +1.64 (11.49) +1.29 (9.48) +3.46 (6.77) +8.51 (8.89) +7.60 (8.57)
MSM +3.51 (5.49) +3.17 (5.49) −2.28 (5.42) −8.60 (6.19) +8.41 (6.36) +2.56 (5.42) −3.01 (4.47) +4.34 (3.46) +0.82 (4.21) +2.20 (4.41)
Caucasian race +11.38 (6.33) +18.93 (6.16)† +4.84 (6.29) −2.75 (7.29) +5.98 (7.52) +10.87 (6.22) +4.29 (5.20) +11.34 (4.04)† +7.52 (4.84) +9.16 (5.23)
Age >45 years +9.04 (5.22) +12.21 (5.16)* +8.24 (5.13) +12.32 (5.87)* +11.00 (6.13) +5.18 (5.17) +6.27 (4.25) +9.25 (3.12)† +9.02 (3.95)* +9.23 (4.02)*
Living alone −0.33 (5.42) −2.15 (5.42) −11.91 (5.18)* −16.74 (5.91)† −6.87 (6.36) −2.18 (5.32) −6.44 (4.35) +2.82 (3.38) −7.05 (4.1) −4.23 (4.29)
Diagnosed <2 years −0.98 (7.27) −22.96 (6.91)† −2.65 (7.13) −3.79 (8.24) −18.98 (8.32)* +4.54 (7.13) +6.54 (5.86) −7.04 (5.61) −5.34 (5.52) −3.04 (7.12)
Unemployed or −23.14 (6.54)‡ −5.95 (6.92) −20.63 (6.49)† −16.88 (7.69)* −2.01 (8.14) −25.92 (6.3)‡ −27.45 (4.91)‡ −10.32 (4.07)* −17.32 (4.99)‡ −16.34 (5.01)†
sickness benefits
Post-secondary +8.44 (5.44) +3.18 (5.5) −0.4 (5.4) −0.8 (6.24) −0.65 (6.47) +3.03 (5.39) +8.22 (4.39) −0.92 (3.42) +3.2 (4.19) +2.17 (4.31)
education
Substance use over previous 2 weeks
Tobacco +1.1 (5.4) +1.49 (5.4) −8.65 (5.22) +6.95 (6.08) +1.75 (6.37) −4.62 (5.28) −7.68 (4.31) −0.81 (3.31) −1.69 (4.13) −1.09 (4.2)
Alcohol −3.29 (7.46) +10.37 (7.41) −0.06 (7.33) +0.04 (8.47) −0.96 (8.76) +4.12 (7.32) +1.92 (6.06) +3.18 (4.44) +1.88 (5.69) +3.57 (5.6)
Variance explained by sociodemographic factors
(proportion) 18.01% 22.49% 19.64% 20.7% 18.74% 20.69% 32.63% 20.6% 22.61% 21.22%
Treatment factors
On ART +1.82 (7.47) +18.94 (7.24)* +5.92 (7.31) +2.57 (8.47) +22.49 (8.46)† +0.27 (7.33) −2.08 (6.06) - +7.00 (5.65) -
Current ART (ref: NNRTI)
none − 3.79 (7.96) −19.27 (7.74)* −7.50 (7.80) −6.44 (8.98) −15.00 (8.80) −2.09 (7.82) −2.99 (6.30) - −7.95 (6.04) -
PI −4.16 (5.75) −0.70 (5.59) −3.35 (5.63) −8.23 (6.48) +15.71 (6.37)* −3.86 (5.65) −10.76 (4.55)* −9.93 (3.10)† −1.99 (4.37) −2.97 (4.13)
H
e
rrm
a
n
n
et
a
l.
H
ea
lth
a
n
d
Q
u
a
lity
o
f
Life
O
u
tco
m
es
2
0
1
3
,
1
1
:5
6
P
a
g
e
7
o
f
1
3
h
ttp
://w
w
w
.h
q
lo
.co
m
/co
n
te
n
t/1
1
/1
/5
6
Table 4 Linear regression estimates of univariate predictors of mean (SE) increase/reduction (+/−) in PROQOL subscale and global scores (body of table),
together with the percent of the score variances explained by fitting joint models of covariate blocks as grouped according to indication of
sociodemographic, treatment, biomedical or clinical factors (R2×100) (Continued)
Time on HAART +0.23 (0.5) +1.38 (0.47)† −0.07 (0.49) −0.04 (0.56) +1.44 (0.57)* −0 (0.48) −0.12 (0.4) +0.36 (0.28) +0.43 (0.38) +0.42 (0.36)
(per year) ^
ART pill burden −2.78 (2) −0.68 (1.96) −2.06 (1.94) −3.74 (2.18) +3.06 (2.36) −2.12 (1.9) −3.06 (1.55) −3.36 (1.08)† −1.56 (1.54) −1.78 (1.43)
(per tablet/day) ^
ART non-adherent^ −2.48 (7.16) +2.13 (6.96) −3.26 (6.93) −7.21 (7.84) −2.8 (8.4) −1.57 (6.79) −6.58 (5.58) −9.22 (3.91)* −2.95 (5.46) −3.72 (5.07)
On non-ART −8.00 (5.41) −2.57 (5.47) −6.05 (5.34) −6.45 (6.17) +8.08 (6.38) −11.07 (5.26)* −12.39 (4.26)† −1.19 (3.34) −5.35 (4.14) −4.61 (4.18)
medication
Variance explained by treatment factors
(proportion) 8.33% 20.27% 4.02% 5.39% 17.01% 6.51% 14.28% 26.55% 10.18% 10.18%
Biological factors
Body mass index
(per unit) −0.01 (0.58) −0.35 (0.58) −0.29 (0.57) +0.20 (0.66) +0.02 (0.68) +0.08 (0.57) −0.18 (0.47) +0.16 (0.35) −0.07 (0.44) −0.01 (0.44)
CD4 count (per 100
T cells) +0.25 (0.82) +1.50 (0.81) +0.30 (0.81) +1.90 (0.91)* +0.22 (0.97) +0.80 (0.80) +0.42 (0.66) +0.88 (0.47) +0.81 (0.62) +0.84 (0.60)
Detectable viral
load −9.13 (6.08) −17.09 (5.92)† −10 (5.95) −6.36 (6.94) −13.05 (7.10) −5.94 (6.01) −0.87 (4.99) −10.52 (4.61)* −8.79 (4.6) −10.96 (5.86)
Variance explained by biological factors
(proportion) 2.99% 11.15% 3.31% 4.57% 3.47% 2.07% 2.49% 10.00% 4.80% 5.51%
Clinical factors
Depressive −27.84 (5.41)‡ −11.26 (5.95) −19.64 (5.63)‡ −20.76 (6.51)† +4.91 (7.12) −17.22 (5.69)† −24.26 (4.27)‡ −6.49 (3.67) −16.48 (4.29)‡ −16.42 (4.29)‡
Other comorbidity −10.5 (5.21)* +0.27 (5.32) −3.97 (5.2) −3.95 (6.02) +9.49 (6.2) −7.59 (5.16) −8.61 (4.23)* −3.35 (3.27) −3.35 (4.06) −4.35 (4.14)
Symptoms
Sexual dysfunction −26.02 (5.57)‡ −22.06 (5.75)‡ −6.69 (6.00) −23.14 (6.58)‡ −12.38 (7.11) −14.88 (5.85)* −23.6 (4.40)‡ −7.86 (3.73)* −18.29 (4.31)‡ −16.03 (4.49)‡
Gastrointestinal −6.73 (1.53)‡ −3.99 (1.63)* −4.2 (1.59)† −5.38 (1.82)† −0.31 (1.97) −5.63 (1.54)‡ −8.57 (1.05)‡ −3.3 (0.94)‡ −4.95 (1.18)‡ −5.06 (1.15)‡
(per number)
Malaise (per −8.11 (1.58)‡ −4.75 (1.71)† −6.44 (1.62)‡ −4.28 (1.97)* +0.17 (2.09) −8.29 (1.53)‡ −9.18 (1.11)‡ −2.21 (1.12) −5.95 (1.22)‡ −5.84 (1.3)‡
number)
Morphological −4.71 (1.36)‡ −2.2 (1.42) −2.75 (1.38)* −5.29 (1.54)‡ −1.04 (1.68) −4.81 (1.33)‡ −4.97 (1.05)‡ −1.76 (0.84)* −3.65 (1.03)‡ −3.66 (1.01)‡
(per number)
Other (per number) −8.39 (2.5)† −4.6 (2.6) −5.32 (2.53)* −4.34 (2.96) −0.8 (3.15) −11.06 (2.34)‡ −9.17 (1.93)‡ −2.48 (1.58) −6.71 (1.93)‡ −7.01 (1.91)‡
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Table 4 Linear regression estimates of univariate predictors of mean (SE) increase/reduction (+/−) in PROQOL subscale and global scores (body of table),
together with the percent of the score variances explained by fitting joint models of covariate blocks as grouped according to indication of
sociodemographic, treatment, biomedical or clinical factors (R2×100) (Continued)
Variance explained by clinical factors
(proportion) 37.25% 19.37% 19.68% 21.82% 6.7% 29.97% 62.04% 14.2% 31.92% 33.31%
Variance explained by all factors
(proportion) 63.64% 49.81% 37.24% 46.31% 33.07% 41.26% 75.36% 47.83% 53.01% 55.4%
^Analysis restricted to treated patients only.
P-values: ‡ P<0.001; † 0.001≤P<0.01; * 0.01≤ P<0.05.
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Assessment of HRQL
Quality of life outcomes were assessed in terms of both
the global PROQOL score and the 8-subscale scores.
The global 7-factor score had an observed mean (SE) of
60.62 (2.01), with mean subscale scores ranging from
43.32 (ST) to 72.55 (SR). Restricting to the treated pa-
tients only, scores were slightly higher across all domains
except the physical health score, with the highest
subscale being that measuring treatment impact. Inclu-
sion of this latter domain resulted in an increase of the
global mean from 61.66 (2.21) for the 7-factor score to
64.07 (2.06) for the 8-factor score.
Univariate regression analyses of demographic associa-
tions with the PROQOL global and subscale scores are
presented in Table 4, with covariates grouped according
to indication of sociodemographic, treatment, biological
and clinical factors. As a whole, sociodemographic fac-
tors had a notable impact across all sub-scales. Profes-
sional activity was particularly discerning, with patients
unemployed or on sickness benefits reporting consist-
ently lower HRQL across the domains. Other factors
were more domain-specific. Those living alone were sig-
nificantly more impacted by difficulties with intimate
relationships compared with those living with others
(p = 0.006), whereas older age was associated with higher
HRQL scores in this domain. Worry over HIV and
other health outcomes, for example test results and
catching other infections, was less common in Caucasians
(p = 0.003) and older patients (p = 0.02), However, those
recently diagnosed (<2 years) were more likely to express
health concerns (p = 0.001) and, with lower scores in the
stigma domain, indicate fear of disclosing their HIV status
and infecting others (p = 0.02).
Amongst patients receiving treatment, class of ART
and adherence were independently associated with the
domain capturing treatment impact; lower scores were
observed amongst those on a protease inhibitor and
those reporting less than 100% adherence (p = 0.005 and
p = 0.048, respectively, in a joint model). Treatment-related
factors impacted on other subscales as well. Patients on a
protease inhibitor or taking medication for non-HIV
comorbidities also recorded lower scores pertaining to
physical health and symptoms. Furthermore, duration of
ART, in particular, was positively associated with higher
scores in both the health concern and stigma domains
(p < 0.007), indicating an attenuation of anxiety over time.
Accordingly, those receiving protease inhibitor-based ART
who on average had been on therapy for 3 years longer
than patients receiving NNRTI-based therapy, appeared
less affected by issues of stigmatization.
Negatively impacting on HRQL across many of the
subscale scores were clinical factors: suffering from
depression, another comorbidity, sexual dysfunction and
frequency of experienced symptoms. The number of
symptoms, in particular, was highly predictive of reduced
HRQL across all domains except stigma. Symptoms
were more prevalent amongst patients receiving PI regi-
mens (mean (SE) number = 8 (0.85)) compared with
those on NNRTI regimens (5.48 (0.80), p = 0.005,
Mann–Whitney test) but were not confined to patients
receiving ART (Figure 1). Symptoms of malaise, particu-
larly, were common across all three groups, as were in-
somnia and skin problems.
Consistent with the observed impact of clinical factors
across most of the sub-scales, lower global PROQOL-
HIV scores were strongly associated with occurrence of
symptoms, depression or other comorbidities (Table 4).
When considered together in multivariable models these
clinical factors explained over 30% of the variability in
both the 7-factor and 8-factor global scores, contrasting
Figure 1 Patient reported symptoms and associated distress.
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with about 20% for the sociodemographic factors alone,
10% for the treatment factors and about 5% for the bio-
logical parameters. However, due to a lack of independ-
ence of the contributing factors their combined impact
is not additive, and only a total of 55% of the PROQOL-
HIV score variation could be explained by the complete
covariate set.
Scores pertaining to stigma as captured by the PROQOL
instrument were lower, on average, than all other domains
and notable for lack of significant association with any of
the clinical factors considered. This subscale is comprised
of items pertaining to fear of disclosure of HIV status and
transmitting the infection and there was a strong correl-
ation between having a high frequency of these two fears
(p = 0.0001), with 33% of participants reporting that fears
of both disclosure and infecting others were often/always
on their mind. These patients had consistently lower
scores spread across subscales other than the stigma
domain, particularly in the areas of emotional distress
(p = 0.02), intimate relations (p = 0.0007), social rela-
tionships (p = 0.04) and health concerns (p < 0.0001).
Whilst there appeared to be some attenuation of
stigmatization with time, a substantial proportion of pa-
tients with these issues frequently on their mind had been
on treatment for some time: 50% for at least 3 years and
25% for more than 7 years.
Discussion
We have presented a thorough analysis of observational
HRQL data in a single cohort using established qualita-
tive methods and the new psychometric instrument,
PROQOL-HIV. This is the first comprehensive study of
HRQL in Western Australia since the HIV epidemic
began thirty years ago. The results from the survey, sup-
ported by the interview material, demonstrate that HIV
influences HRQL across the spectrum of biological, social
and psychological domains that comprise the complex
continuum of measures of health [28]. In particular, people
reporting: unemployment, depression, and a higher fre-
quency of symptoms, particularly those impacting nega-
tively on sexual expression, scored a poorer quality of life
overall, independently of other factors and regardless of
ART status. Interview respondents struggling with roman-
tic relationships described feelings of loss around cessation
of sexual practices relinquished to prevent transmission;
opportunities to engage in sexual activity without the bur-
den of disclosure; fear of rejection and the potential for
transmission despite use of safer sex strategies. Accord-
ingly, the novel instrument has captured a dimension of
HIV-related stigma, by way of an individual’s fear of dis-
closing their HIV serostatus and/or transmitting the infec-
tion that clearly results in emotional distress. Therefore,
although the HIV/AIDS-Targeted Quality of Life Instru-
ment (HAT-QOL) has a dimension for disclosure concerns
[29], the PROQOL–HIV questionnaire goes a step further
and juxtaposes anxiety about transmitting the infection
with fear of disclosure.
In concordance with Lee’s research [30], the survey
showed that feelings of stigma were heightened in those
more recently diagnosed in contrast with those who had a
longer history of HIV infection. These included the small
number of patients infected via IDU who had a relatively
long time since diagnosis (mean=12 years) and might be
expected to experience compound stigma related to their
membership of another marginalised group [31]. However,
more than half of survey respondents expressing stigma
concerns had been on therapy for over three years; and
the interviews highlighted persistent concern that HIV-
related stigma negatively affected relationships and em-
ployment opportunities, consistent with other studies
[11,12,32,33]. Courtenay-Quirk and colleagues [34] found
that avoidant coping strategies, anxiety, loneliness, depres-
sive symptoms, and suicidal ideation were associated with
HIV-related stigma in a community of HIV-positive men;
and Holzemer [35] showed that stigma had a negative ef-
fect on quality of life independently of HIV-related symp-
toms and severity of illness. More recently Hutton and
others [36], using the Personal Well Being Index [37]
reported that stigma impacted negatively on subjective
well-being in PLWH in Australia and the USA by way of
perceived unsupportive (hurtful) social interactions.
While HIV-related stigma has been associated with de-
pression [38], and specific concerns such as serostatus dis-
closure fears and transmission anxiety have been reported
[11,30,39], we could not find evidence in the literature
suggesting that transmission anxiety per se is a specific
stressor in HIV-related depression and contagion fears ap-
pear more commonly addressed in uninfected individuals
[40,41]. Cognitive behavioural interventions have been
trialed to decrease HIV-related stigma and a recent study
reported that an intervention improving personal control
via a sense of mastery and increased social support may be
beneficial in reducing stigma in people with depressive
symptoms [38,40].
It was somewhat surprising then that reported depres-
sion did not correlate with the stigma domain in our
study, and it is concerning that the fear of infecting
others, which in some individuals resulted in avoidant
behaviour out of proportion to risk, may not be uncov-
ered in the course of clinical consultations. Since stigma
may be nuanced by its various associations with sex,
gender, death and ethnicity [31] and deeply internalised
[13] it could be examined by assessing the limitations that
people place upon their lives as a result of the anxiety.
A number of demographic factors contributed to a di-
minished perception of HRQL among the respondents
to the interviews and the questionnaires. Notably, people
living alone cited restricted intimate and/or social
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relationships, although whether this was as a result of
self withdrawal or inhibition with regard to disclosing
HIV status, or some other reason, is not clear. Older age
and longer duration of HIV were associated with an im-
provement in HRQL, as observed by others [42]. In par-
ticular, older Caucasians were less troubled by health
concerns related to regular CD4 and viral load monitor-
ing and progression of the disease, perhaps reflecting
their adjustment to diagnosis, better knowledge of the
disease and/or greater confidence in the treatment,
reinforced by successful treatment outcomes. However,
unemployment and disability resulted in diminished
HRQL regardless of age and the interviews revealed a
picture of social isolation and physical discomfort not
necessarily directly attributable to HIV disease.
People on PIs reported more symptoms, especially gas-
trointestinal, and more tablets overall compared with those
on NNRTI regimens. This translated into greater treatment
impact, but not into reduced HRQL overall, most likely be-
cause of improvements in overall physical health and per-
haps psychosocial adjustments associated with the longer
average duration of ARTand time since diagnosis. The level
of adherence in our patients was higher than in the other
cohorts in the international study [23], perhaps reflecting
once daily dosing, but we did not find a direct relationship
between adherence and global HRQL. However, non-
adherence to ART remained predictive of lower treatment
impact scores over and above treatment choice and viral
load. This finding suggests that the benefits of treatment
were not perceived by non-adherent participants.
The study had been sufficiently powered to show sig-
nificant site-specific effects of covariates on HRQL do-
mains. However, the fact that the combined covariate
sets explained only 55% in the PROQOL-HIV score vari-
ation suggests the total score may incorporate facets
additional to quality of life specifically related to HIV,
and is assessing additional information from a patient
perspective that cannot be adequately inferred from the
usual sociodemographic or biological variables. This
finding concurs with Wilson’s [43] conceptual model
suggesting that total HRQL is substantially impacted by
some hard-to-measure factors relating to personality,
which may contribute to resilience and coping.
There were limitations to our study. Cross-sectional de-
sign is less robust than longitudinal measurement where
responses are measured over a period of time; however
the qualitative component strengthens the internal validity
of the study. The closed-ended format of the question-
naires did not accommodate explanations, but the ques-
tions were derived from the themes gathered in the
interviews where patients qualified their responses to
semi-directive questions freely.
The development of PROQOL-HIV, has allowed the
measurement of dimensions not assessed in the past.
Application in our local setting has demonstrated that
the instrument will provide a useful tool in cohort ana-
lysis to assess health-related quality of life in general,
and those that result from treatment interventions in
particular. Inclusion of a stigma domain adds further
utility since it is evident that stigma is a persistent fea-
ture of HIV infection and may result in emotional harm,
particularly in those less resilient. The multiple nuances
of stigma should be disentangled in future research in
order to develop suitable interventions. In conclusion,
disease-specific HRQL instruments can bring additional
information to the classical criteria for evaluating clinical
outcomes and should be part of studies evaluating health
policy and treatment strategies [44].
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